2021
Clinical Efficacy of Olaparib in IDH1/IDH2-Mutant Mesenchymal Sarcomas
Eder JP, Doroshow DB, T. K, Keedy VL, Sklar JS, Glazer P, Bindra R, Shapiro GI. Clinical Efficacy of Olaparib in IDH1/IDH2-Mutant Mesenchymal Sarcomas. JCO Precision Oncology 2021, 5: 466-472. PMID: 34994649, PMCID: PMC9848565, DOI: 10.1200/po.20.00247.Peer-Reviewed Original ResearchConceptsPulmonary epithelioid hemangioendotheliomaStable diseaseEpithelioid hemangioendotheliomaClinical benefitClinical benefit rateOpen-label studyPrimary end pointPoly (ADP-ribose) polymerase inhibitionDefective homologous recombination (HR) repairMesenchymal sarcomaObjective responsePartial responseClinical efficacyPatient populationBenefit rateCombination trialsPatientsSolid tumorsIDH1/2-mutant tumorsIDH1/2 mutationsPARP inhibitorsEnd pointPARP inhibitionTumorsOlaparib
2000
Cyclin D1 expression and early breast cancer recurrence following lumpectomy and radiation
Turner B, Gumbs A, Carter D, Glazer P, Haffty B. Cyclin D1 expression and early breast cancer recurrence following lumpectomy and radiation. International Journal Of Radiation Oncology • Biology • Physics 2000, 47: 1169-1176. PMID: 10889369, DOI: 10.1016/s0360-3016(00)00525-3.Peer-Reviewed Original ResearchConceptsIpsilateral breast tumor recurrenceBreast cancer patientsDistant disease-free survivalCancer patientsRadiation therapyOverall survivalEarly-stage breast cancer patientsEarly breast cancer recurrenceAxillary lymph node involvementCycD1 expressionTotal median doseBreast tumor recurrenceDisease-free survivalLymph node involvementBreast cancer populationBreast cancer recurrenceBreast tumor relapseCyclin D1 expressionCyclin D1 levelsMedian doseNode involvementMetastatic diseaseLate relapsePrognostic significancePatient population